Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Dementia × 30 days × Clear all

Phase

Phase 3 2 Phase NA 1 Phase 4 1 Phase 2/3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 7 Prostatic Neoplasms 5 Neoplasms 5 Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Myasthenia Gravis 4 Lung Neoplasms 4 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Fallopian Tube Neoplasms 3 Urinary Bladder Neoplasms 2 Recurrence 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Carcinoma 2 Myelodysplastic Syndromes 2 Melanoma 2 Liposarcoma 2 Leukemia, Myelomonocytic, Chronic 2 Laryngeal Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Adenocarcinoma Of Esophagus 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Ulcer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06125951 2026-02-18

XanaMIA

Actinogen Medical

Phase 2/3 Active not recruiting

Alzheimer Disease, Dementia, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡